Common questions from consultants and brokers

We run a medication-level review of the client's pharmacy claims, identify the medications driving spend, compare available acquisition pathways, including domestic-only options, and support the selected implementation. The program can work alongside existing PBM, carrier, and consultant relationships, but plan and administrative requirements vary by path. You keep the client relationship.

There is no upfront consulting fee and no separate advisory invoice. Limitless is compensated inside the selected vendor's pricing. The client can evaluate the opportunity before committing to anything.

Not necessarily, but requirements vary. PSP® starts with a focused medication-level review and can work alongside existing PBM, carrier, and consultant relationships. Some selected paths may require plan or administrative changes. We identify those requirements before the employer decides whether to proceed.

A top 25 or top 50 drug list is enough for a first read. A twelve month claims extract produces a tighter estimate. Send de-identified data only. No member names, dates of birth, or member ID numbers.

Personal importation is not an unrestricted legal right. FDA applies enforcement discretion and reviews situations on their specific facts. Each sourcing pathway is assessed against the client's plan structure and the vendor's documentation, and some pathways are domestic. This is educational information, not legal advice.